Compare ENVX & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENVX | IMCR |
|---|---|---|
| Founded | 2006 | 2008 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.7B |
| IPO Year | 2020 | 2016 |
| Metric | ENVX | IMCR |
|---|---|---|
| Price | $6.93 | $29.35 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 10 |
| Target Price | $13.61 | ★ $66.33 |
| AVG Volume (30 Days) | ★ 5.2M | 356.8K |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 40.94 | 30.39 |
| EPS | N/A | ★ 0.25 |
| Revenue | $31,821,000.00 | ★ $249,428,000.00 |
| Revenue This Year | $30.37 | $14.57 |
| Revenue Next Year | $238.73 | $8.21 |
| P/E Ratio | ★ N/A | $115.36 |
| Revenue Growth | 37.91 | ★ 43.05 |
| 52 Week Low | $4.67 | $27.47 |
| 52 Week High | $16.49 | $40.71 |
| Indicator | ENVX | IMCR |
|---|---|---|
| Relative Strength Index (RSI) | 58.91 | 46.82 |
| Support Level | $6.68 | $28.90 |
| Resistance Level | $8.66 | $34.35 |
| Average True Range (ATR) | 0.44 | 1.32 |
| MACD | -0.00 | 0.11 |
| Stochastic Oscillator | 61.94 | 46.62 |
Enovix Corp is engaged in designing, developing, manufacturing, and commercializing Lithium-ion, or Li-ion, battery cells. It uses BreakFlow and Encapsulation technologies to manufacture high capacity and resilient batteries. The company's product portfolio comprises power disc batteries, flexible lithium-ion polymer batteries, superior lithium-ion polymer batteries, active silicon lithium-ion cells, and others. Geographically, the company generates maximum revenue from its customers in South Korea, followed by Switzerland, the United States, Norway, Taiwan, and other regions.
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.